Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2020 Feb 12;522(3):763-769. doi: 10.1016/j.bbrc.2019.11.162. Epub 2019 Nov 29.

MBNL1 regulates resistance of HeLa cells to cisplatin via Nrf2.

Author information

1
Obstetrics and Gynecology Department, Yuncheng County People's Hospital, Shandong Province, China.
2
Clinical Laboratory, Hubei University Hospital, Hubei Province, China.
3
Surgery, Hubei University Hospital, Hubei Province, China. Electronic address: superdaddy@163.com.

Abstract

Chemotherapy is an important method in the treatment of cervical cancer, but some patients will face drug resistance, which often indicates a poor prognosis. Moreover, there is no complete solution at present. Therefore, it is urgent to study the drug resistance mechanism of cervical cancer. Based on sequencing data mining, we predicted that MBNL1 might be involved in the occurrence and poor prognosis of cervical cancer, and verifed that MBNL1 could regulate the resistance of HeLa cells to cisplatin via Nrf2. In addition, we demonstrated that MBNL1 up regulated the degradation of Nrf2 protein by increasing the mRNA stability of Cul3. These results can provide theoretical basis for clinical development of new diagnosis and treatment targets for cisplatin resistance.

KEYWORDS:

Cisplatin resistance; Cul3; HeLa; MBNL1; Nrf2

PMID:
31791583
DOI:
10.1016/j.bbrc.2019.11.162

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center